GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings onlyH.C. Wainwright Global Investment Conference in New York, NY Tuesday, September 9, 2025 Fireside chat at 8:30 a.m. Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.Morgan Stanley Global Healthcare Conference in New York, NYWednesday, September 10, 2025 Fireside chat at 7:45 a.m. Eastern Time The session will be webcast and can...

Monthlong initiative rewards customers who engage with responsible gaming tools, including the new “My Budget Builder” BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) — DraftKings Inc. (NASDAQ: DKNG) is marking Responsible Gaming Education Month (RGEM) with a monthlong campaign designed to promote responsible play. At the center of the effort is the launch of a sweepstakes—offering customers the chance to win NFL tickets, including a grand prize trip to Super Bowl LX, by engaging with tools like My Budget Builder and My Stat Sheet. As the NFL season kicks off, DraftKings is combining new technology with meaningful initiatives to encourage responsible play and help customers make more informed choices. “We are excited to launch our sweepstakes initiative in celebration of Responsible Gaming Education Month, inviting customers to explore...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of sigmar-1 receptor (S1R/SIGMAR1) through blarcamesine activation, titled “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.”1 The mechanistic confirmation that blarcamesine restores impaired autophagy through S1R/SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular...

RYE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) — The Board of Trustees of Ellsworth Growth and Income Fund Ltd. (NYSE American: ECF) (the “Fund”) increased the quarterly distribution to $0.19 per share. The increased quarterly distributions will commence with the distribution payable in December 2025. This is a 20% increase from $0.16 per share, bringing the annualized distribution rate to $0.76 from $0.64 per share. The increase reflects the strength of the Fund’s NAV total return of 18% year to date. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call: Bethany Uhlein(914) 921-5546 About Ellsworth Growth and Income Fund Ellsworth Growth and Income Fund Ltd. is...

Event will introduce digital treasury strategies aimed at unlocking value and highlight their potential impact on the Company’s future growth WOODS CROSS, Utah, Aug. 26, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company committed to revolutionizing the waste asphalt shingle recycling industry, today announced that it will host a live investor webinar on Friday, August 29 at 12:00 p.m. PDT / 3:00 p.m. EDT. The webinar will provide an introductory look at how digital treasury strategies could play a role in Sky Quarry’s long-term growth. Marcus Laun, President and Interim CFO of Sky Quarry will discuss why these emerging strategies are gaining global attention, how they may act as potential game changers for traditional industries,...

Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamics AVIM therapy drove statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no adverse impact on stroke volume or contractility. Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration for the development of AVIM therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker; over 750,000 patients annually that receive pacemakers worldwide are also believed to have hypertension.  AVIM therapy has FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, a population...

MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10). Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at both conferences being held in New York (NY). Each session will be webcast live, and available on demand following the events. For more information including how to register, please visit the Telix Investor Relations website under events: https://ir.telixpharma.com/events-presentations About Telix Pharmaceuticals Limited...